secwatch.observer — SEC 8-K summary
======================================

Issuer:     Grace Therapeutics, Inc. (GRCE)
CIK:        0001444192
Form:       8-K
Filed at:   2026-08-13T12:01:03+00:00
Accession:  0001140361-26-032644
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Grace Therapeutics Q1 net loss $15.8M, $13.5M IPR&D impairment
--------------------------------------------------------------

- Net loss $15.8M ($0.91/share) vs $3.4M ($0.21) YoY; includes $13.5M impairment of GTx-101/102 IPR&D.
- Cash $22.2M as of Aug 11, 2026; runway through end of 2028; $10M private placement announced.
- FDA Type A meeting minutes received; CRL items are CMC/non-clinical, no clinical safety/efficacy issues.
- Dual-source manufacturing: tech transfer to second U.S. CMO underway; NDA resubmission timing depends on site readiness.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/0001140361-26-032644-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1444192/000114036126032644/ef20079525_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-032644

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer